Now Accepting Call For Sessions Proposals

Search General Info
Search Education
Search Partnering Companies

Now Accepting Call For Sessions Proposals

Call for Sessions Deadline Extended Through October 21, 2021

 

Showcase your thought leadership by creating a session at BIO International Convention 2022. Educate attendees on the most pressing issues and trends affecting the biotech industry while increasing the visibility of your organization’s critical contributions to the field.  The application process has five steps and should only take 30 minutes to complete.

  1. Create an account on BIOs program portal page to save drafts pre-submission. 
  2. Choose your proposal type.
  3. Complete the session proposal form.
  4. Provide speaker information.
  5. Review and submit.

 

 

 

 

 

We’re here to help.

Pro Tips: Before starting your application, we suggest you gather the following information:

  • Topic: There is a broad array of potential focus areas. View the full Track List and Thought-Starters in the table below
  • Session Title: Descriptive titles that emphasize audience benefit work well.
  • Session Type: 
    • Debate: One moderator and no more than two speakers will have an interactive, lively discussion in which they will put forth opposing views on the session topic.
    • How-To Session: Tutorials for the novice or expert in biotech with 1 – 2 speakers. Addresses a specific topic or issue in biotech and provides practical lessons learned. Also, group or solo exercises (e.g., writing examples, brainstorming) may be applicable here.
    • Interactive Panel: Panelists (maximum of 4 plus one moderator) present case studies from multiple perspectives facilitated by a moderator. Moderator will facilitate formal Q&A or polling with the audience and panelists for a minimum of 15 minutes.
    • Interview: One presenter, one moderator. The moderator questions the presenter on the session topic for approximately three-fourths of the time, after which the floor is opened for questions to the presenter from the audience.
    • Single Speaker Proposal: Recommended for a particular topic subject matter expert to be considered for inclusion on a developed panel OR to be considered for a deep-dive presentation with emphasis on data trends and statistical analysis.
  • Audience Ability Level: 
    • All: Appropriate for all knowledge levels, including individuals who are new to the topic/subject area.
    • Intermediate: Intended for individuals who already have a basic knowledge of the topic/subject area and are looking to further their understanding of the subject matter.
    • Advanced: Appropriate for seasoned professionals and experts, this level assumes the audience already grasps the intermediate elements of the topic and is seeking to explore the topic/subject matter with a more in-depth perspective.
  • Session Summary: A brief description of your proposed session and key take-away points for the audience. (Maximum of 1,000 characters)
  • Session Methodology: How you will conduct your session based on format. Consider what each speaker will address and how the session will unfold. (Maximum of 1,000 characters)
  • Speaker Information: In addition to names and general contact information, please have short biographies on hand. Please note: BIO will not reach out to speakers.
  • Elevator Pitch: Single sentence that encapsulates your proposed session

 

Full Track List & Thought Starters
BIO Equality - Diversity, Equity, and Inclusion in Biotech
  • Health Equity Workforce Development
  • Training the Next Generation of Researchers
  • Promoting Economic Development of Marginalized Communities
Biomanufacturing
 
  • Advanced/Innovative Manufacturing Benefits and challenges
Brain Health
  • Latest scientific advances in AI and Big Data applications
  • Addiction
  • New approaches to neurodegeneration
  • Examples of collaborations and novel partnerships
Business Development & Finance
  • Trends in Licensing Deals
  • M&A Valuations and Deal Volume Trends Working with Venture Philanthropy and Non-Dilutive Financing
  • Cross-Border Investor Recruitment Shifting
  • Incubator Business Models
Cell & Gene Therapies and Genome Editing
  • Scientific advances
  • Regulatory and policy changes and challenges
  • New applications
  • Overcoming manufacturing bottlenecks
  • Public engagement and education
Clinical Trials Innovations Diagnostics & Personalized Medicine
  • Futurist Challenges / Precision Medicine Pipeline Outlook (in 2030)
  • Direct to Consumer Genetic Testing (Health Risk Reports)
  • Data and Patient Empowerment / Data Privacy Concerns
  • Drug Target Identification (Biomarker Discovery and Validation)
  • Data Science / Biopharma Partnerships with Data Providers
  • Public, Private and Academic Research Programs (NIH All of Us Research Program, Genome Centers, Biobanks, Databanks)
  • Human Genome Project / Genome Wide Association Studies
  • Innovative Capital Formation Ideas or Trends (e.g., Diagnostics Companies vs. Tech Companies)
  • Companion Diagnostics for Targeted Therapies
  • Scientific and Technological Advances in Sequencing
Digital Health    
  • AI-Driven Molecular Modeling Clinical Trial Support Tools
  • Patient-Reported Outcomes Data and Real-World Evidence
  • Prescription Digital Therapeutics Apps Algorithm and Data Bias Transparency
  • Digital Health Technology Tools
Emerging Issues
  • Solving new challenges through biotechnology
  • Industry issues on the horizon New, innovative topics
Emerging Opportunities in Global Markets
  • Policies/challenges to fostering biotech innovation globally
  • Value/access opportunities/challenges in global markets
  • Reducing trade barriers Brexit
Infectious Disease & Vaccines
  • Global health and infectious diseases
  • Antimicrobial resistance
  • Clinical integration of infectious disease diagnostics
  • Data analytics/AI in infectious disease R&D
  • Influenza
  • Nagoya Protocol & access and benefits sharing for infectious disease pathogens
  • Next generation antibodies
  • Novel vaccine delivery systems
  • Pandemic preparedness
  • Partnerships with developing country manufacturers
  • Platforms/rapid technologies for infectious diseases
  • Real-world evidence for vaccines and infectious disease therapeutics
Intellectual Property
  • 101 updates
  • Biologic patent litigation Case law updates
  • International IP framework comparisons Drug pricing update
Next Generation Biotherapeutics
  • Microbiome Organ on a Chip Exosomes
  • RNA-based therapies

Oncology

  • Latest scientific advances
  • Regulatory and Policy changes
  • Partnerships & Deal-making
One Health
  • One Health Zoonotic diseases
  • Antimicrobial resistance
  • Mosquito-borne diseases
  • Human, animal, environmental health Cross-sectoral solutions/innovations
  • Climate change
Orphan & Rare Disease
  • Collaborative research model case studies
  • Reimbursement models
  • Business development trends
  • Clinical trial design
  • Natural history
Patient Advocacy
  • Patient Access
  • Best practices to achieve successful partnerships
  • Patient Voice in AMR and Vaccine Confidence
  • Patient Voice in Value Conversations
Regulatory Innovation
  • PDUFA VIIPFDD
  • Real World Evidence
  • Decentralized Clinical Trials
  • Cost of regulatory-based policy incentives
  • Innovative Clinical Trial Designs
Translational Research
  • Examples of new models for collaboration
  • Best practices for public-private partnerships
  • De-risking academic science
Value, Patient Access & Reimbursement
  • Policy issues/priorities
  • Innovative reimbursement models
  • Value-based payments
  • The role of value assessment frameworks